Eurosurv. The SARS-CoV-2 Lambda variant and its neutralisation efficiency following vaccination with Comirnaty, Israel, April to June 2021

[tetano]

• Neta Zuckerman[SUP]1[/SUP] , Ital Nemet[SUP]1[/SUP] , Limor Kliker[SUP]1[/SUP] , Nofar Atari[SUP]1[/SUP] , Yaniv Lustig[SUP]1,2[/SUP] , Efrat Bucris[SUP]1[/SUP] , Dana Bar Ilan[SUP]1[/SUP] , Miranda Geva[SUP]1[/SUP] , Reut Sorek-Abramovich[SUP]3[/SUP] , Chen Weiner[SUP]3[/SUP] , Nir Rainy[SUP]3[/SUP] , Adina Bar-Chaim[SUP]3[/SUP] , Patricia Benveniste-Levkovitz[SUP]3[/SUP] , Ramzia Abu Hamed[SUP]3[/SUP] , Gili Regev-Yochay[SUP]2,4[/SUP] , Ofra Hevkin[SUP]5[/SUP] , Orna Mor[SUP]1,2[/SUP] , Sharon Alroy-Preis[SUP]5[/SUP] , Ella Mendelson[SUP]1,2,*[/SUP] , Michal Mandelboim[SUP]1,2,*[/SUP]

The SARS-CoV-2 Lambda (Pango lineage designation C.37) variant of interest, initially identified in Peru, has spread to additional countries. First detected in Israel in April 2021 following importations from Argentina and several European countries, the Lambda variant infected 18 individuals belonging to two main transmission chains without further spread. Micro-neutralisation assays following Comirnaty (BNT162b2 mRNA, BioNTech-Pfizer) vaccination demonstrated a significant 1.6-fold reduction in neutralising titres compared with the wild type virus, suggesting increased susceptibility of vaccinated individuals to infection.

full article

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.45.2100974#html_fulltext